27th Sep 2016 10:59
For filings with the FCA include the annex | |||||
For filings with issuer exclude the annex | |||||
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | |||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | 4D Pharma plc | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | √ | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | √ | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): | |||||
3. Full name of person(s) subject to thenotification obligation: iii | Aviva plc & its subsidiaries | ||||
4. Full name of shareholder(s) (if different from 3.):iv | Registered Holder:
BNY Norwich Union Nominees Limited 67,420*
Chase (GA Group) Nominees Limited 956,872* * denotes direct interest
| ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 23 September 2016 | ||||
6. Date on which issuer notified: | 26 September 2016 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 3% to | ||||
8. Notified details: | |||||||||||
A: Voting rights attached to shares viii, ix | |||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | |||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||
Ordinary Shares GB00BJL5BR07 |
3,235,222* |
3,235,222* |
1,024,292 |
1,024,292 |
Not disclosable |
1.58% |
Not disclosable | ||||
* Includes Right to Recall Loaned Shares (617,754)
| |||||||||||
B: Qualifying Financial Instruments | |||||||||||
Resulting situation after the triggering transaction | |||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | |||||||
RIGHT TO RECALL LOANED SHARES | N/A | N/A |
830,203*
* Direct Interest | 1.28% | |||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |
Nominal | Delta | |||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
1,854,495 | 2.86% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | |
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| |
Proxy Voting: | |
10. Name of the proxy holder: | See Section 4 |
11. Number of voting rights proxy holder will ceaseto hold: | |
12. Date on which proxy holder will cease to holdvoting rights: |
13. Additional information: | Figures are based on the total number of voting rights of 64,858,150 as per the Company's 'Acquisition' announcement of 8 April 2016.
|
14. Contact name: | Neil Whittaker, Aviva plc |
15. Contact telephone number: | 01603 684420 |
Related Shares:
AvivaDDDD.L